The phenotypic heterogeneity of severe hemophilia

Seminars in Thrombosis and Hemostasis

Volumn 34, Issue 1, 2008, Pages 128-141

  Jayandharan, Giridhara Rao ^a   Srivastava, Alok ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Hemophilia; Heterogeneity; Phenotype

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 9; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIAL PROTEIN C RECEPTOR; FC RECEPTOR; FIBRINOGEN; GAMMA INTERFERON; HLA B27 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LYMPHOTOXIN; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; ARTHROPATHY; BLEEDING; BLOOD CLOTTING; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; FIBRINOLYSIS; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; HEMOPHILIA; HEMOSTASIS; HUMAN; INFLAMMATION; JOINT INJURY; PHENOTYPE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SYNOVIUM;

HEMOPHILIA A; HEMOPHILIA B; HEMORRHAGE; HEMOSTASIS; HUMANS; JOINT DISEASES; MALE; PHENOTYPE;

EID: 43149085056     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-2008-1066024     Document Type: Review

References (107)

1. Schramm W, Royal S, Kroner B, et al. Clinical outcomes and resource utilization associated with haemophilia care in Europe. Haemophilia 2002;8:33-43
2. Molho P, Rolland N, Lebrun T, et al. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study Group, secretariat. haemophiles@cch.ap-hop-paris.fr. Haemophilia 2000;6:23-32
3. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994;236:391-399
4. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet 2003;361:1801-1809
5. Beutler E. Discrepancies between genotype and phenotype in hematology: an important frontier. Blood 2001;98:2597-2602
6. Astermark J, Oldenburg J, Escobar M, White GC II, Berntorp E. The Malmo International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A. Haematologica 2005; 90:924-931
7. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-1457
8. van Dijk K, van der Bom JG, Fischer K, Grobbee DE, van den Berg HM. Do prothrombotic factors influence clinical phenotype of severe haemophilia? A review of the literature. Thromb Haemost 2004;92:305-310
9. van Dijk K, van der Bom JG, Lenting PJ, et al. Factor VIII half-life and clinical phenotype of severe hemophilia A. Haematologica 2005;90:494-498
10. Handelsman JE. The knee joint in hemophilia. Orthop Clin North Am 1979;10:139-173
11. Hoskinson J, Duthie RB. Management of musculoskeletal problems in the hemophilias. Orthop Clin North Am 1978;9:455-480
12. Stein H, Duthie RB. The pathogenesis of chronic haemophilic arthropathy. J Bone Joint Surg Br 1981;63B: 601-609
13. Hooiveld MJ, Roosendaal G, Jacobs KM, et al. Initiation of degenerative joint damage by experimental bleeding combined with loading of the joint: a possible mechanism of hemophilic arthropathy. Arthritis Rheum 2004;50:2024-2031
14. Arnold WD, Hilgartner MW. Hemophilic arthropathy. Current concepts of pathogenesis and management. J Bone Joint Surg Am 1977;59:287-305
15. van den Berg HM, De Groot PH, Fischer K. Phenotypic heterogeneity in severe hemophilia. J Thromb Haemost 2007; 5(Suppl 1):151-156
16. Fischer K, van der Bom JG, Mauser-Bunschoten EP, et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 2002; 99:2337-2341
17. Pollmann H, Richter H, Ringkamp H, Jurgens H. When are children diagnosed as having severe haemophilia and when do they start to bleed? A 10-year single-centre PUP study. Eur J Pediatr 1999;158(Suppl 3):S166-S170
18. Ramgren O. Haemophilia in Sweden. III. Symptomatology, with special reference to differences between haemophilia A and B. Acta Med Scand 1962;171:237-242
19. Rainsford SG, Hall A. A three-year study of adolescent boys suffering from haemophilia and allied disorders. Br J Haematol 1973;24:539-551
20. van Dijk K, Fischer K, van der Bom JG, Grobbee DE, van den Berg HM. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed. Haemophilia 2005;11:438-443
21. Blanchette P, Rivard G, Israels S, et al. A survey of factor prophylaxis in the Canadian haemophilia A population. Haemophilia 2004;10:679-683
22. Grunewald M, Siegemund A, Grunewald A, Konegan A, Koksch M, Griesshammer M. Paradoxical hyperfibrinolysis is associated with a more intensely haemorrhagic phenotype in severe congenital haemophilia. Haemophilia 2002;8:768-775
23. Arbini AA, Mannucci PM, Bauer KA. Low prevalence of the factor V Leiden mutation among "severe" hemophiliacs with a "milder" bleeding diathesis. Thromb Haemost 1995; 74:1255-1258
24. Beltran-Miranda CP, Khan A, Jaloma-Cruz AR, Laffan MA. Thrombin generation and phenotypic correlation in haemophilia A. Haemophilia 2005;11:326-334
25. Shetty S, Vora S, Kulkarni B, et al. Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients. Br J Haematol 2007;138:541-544
26. Srivastava A. Dose and response in haemophilia-optimization of factor replacement therapy. Br J Haematol 2004;127:12-25
27. Gilbert MS. Prophylaxis: musculoskeletal evaluation. Semin Hematol 1993;30:3-6
28. Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res 1980;149:153-159
29. Poonnoose PM, Srivastava A. Functional assessment of arthropathy-an international perspective. Semin Hematol 2006;43:S27-S32
30. Dargaud Y, Meunier S, Negrier C. Haemophilia and thrombophilia: an unexpected association! Haemophilia 2004;10:319-326
31. Shima M, Matsumoto T, Fukuda K, et al. The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C). Thromb Haemost 2002;87:436-441
32. Escuriola Ettingshausen C, Halimeh S, Kurnik K, et al. Symptomatic onset of severe hemophilia A in childhood is dependent on the presence of prothrombotic risk factors. Thromb Haemost 2001;85:218-220
33. Ghosh K, Shetty S, Mohanty D. Milder clinical presentation of haemophilia A with severe deficiency of factor VIII as measured by one-stage assay. Haemophilia 2001;7:9-12
34. Sorensen B, Ingerslev J. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J Thromb Haemost 2004;2:102-110
35. Dargaud Y, Beguin S, Lienhart A, et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005;93:475-480
36. Siegemund T, Petras S, Siegemund A, Scholz U, Engelmann L. Thrombin generation in severe haemophilia A and B: the endogenous thrombin potential in platelet-rich plasma. Thromb Haemost 2003;90:781-786
37. Matsumoto T, Shima M, Takeyama M, et al. The measurement of low levels of factor VIII or factor K in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay. J Thromb Haemost 2006;4:377-384
38. Chandler WL, Rodgers GM, Sprouse JT, Thompson AR. Elevated hemostatic factor levels as potential risk factors for thrombosis. Arch Pathol Lab Med 2002;126:1405-1414
39. Lee DH, Walker IR, Teitel J, et al. Effect of the factor V Leiden mutation on the clinical expression of severe hemophilia A. Thromb Haemost 2000;83:387-391
40. Nowak-Götd U, Escuriola C, Kurnik K, et al. Haemophilia and thrombophilia. What do we learn about combined inheritance of both genetic variations? Hamostaseologie 2003;23:36-40
41. Jayandharan GR, Nair SC, Poonoose P, et al. Polymorphisms in coagulant and inflammatory genes modify the phenotype of severe hemophilia A and B. J Thomb Haemost 2007;5(Suppl 1):P_W_681
42. van Dijk K, van der Bom JG, Fischer K, de Groot PG, van den Berg HM. Phenotype of severe hemophilia A and plasma levels of risk factors for thrombosis. J Thromb Haemost 2007;5:1062-1064
43. Mosnier LO, Lisman T, van den Berg HM, Nieuwenhuis HK, Meijers JC, Bouma BN. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. Thromb Haemost 2001;86:1035-1039
44. Jayandharan G, Shaji RV, Baidya S, Nair SC, Chandy M, Srivastava A. Identification of factor VIII gene mutations in 101 patients with haemophilia A: mutation analysis by inversion screening and multiplex PCR and CSGE and molecular modelling of 10 novel missense substitutions. Haemophilia 2005;11:481-491
45. Jayandharan GR, Shaji RV, Baidya S, Nair SC, Chandy M, Srivastava A. Molecular characterization of factor IX gene mutations in 53 patients with haemophilia B in India. Thromb Haemost 2005;94:883-886
46. Goodeve AC, Peake IR. The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development. Semin Thromb Hemost 2003;29:23-30
47. Bertina RM. Elevated clotting factor levels and venous thrombosis. Pathophysiol Haemost Thromb 2003/2004;33: 395-400
48. Endler G, Mannhalter C. Polymorphisms in coagulation factor genes and their impact on arterial and venous thrombosis. Clin Chim Acta 2003;330:31-55
49. Iacoviello L, Di Castelnuovo A, De Knijff P, et al. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med 1998;338: 79-85
50. Frere C, Morange PE, Saut N, et al. Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact. Thromb Haemost 2005;94:373-379
51. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10: 111-113
52. Hooiveld M, Roosendaal G, Vianen M, van den Berg M, Bijlsma J, Lafeber F. Blood-induced joint damage: longterm effects in vitro and in vivo. J Rheumatol 2003;30:339-344
53. Roosendaal G, Vianen ME, Wenting MJ, et al. Iron deposits and catabolic properties of synovial tissue from patients with haemophilia. J Bone Joint Surg Br 1998;80: 540-545
54. Hakobyan N, Kazarian T, Jabbar AA, Jabbar KJ, Valentino LA. Pathobiology of hemophilic synovitis I: overexpression of mdm2 oncogene. Blood 2004;104:2060-2064
55. Nishiya K. Stimulation of human synovial cell DNA synthesis by iron. J Rheumatol 1994;21:1802-1807
56. Morris CJ, Blake DR, Wainwright AC, Steven MM. Relationship between iron deposits and tissue damage in the synovium: an ultrastructural study. Ann Rheum Dis 1986; 45:21-26
57. Wen FQ, Jabbar AA, Chen YX, Kazarian T, Patel DA, Valentino LA. c-myc proto-oncogene expression in hemophilic synovitis: in vitro studies of the effects of iron and ceramide. Blood 2002;100:912-916
58. Petrovic-Rackov L, Pejnovic N. Clinical significance of IL-18, IL-15, IL-12 and TNF-alpha measurement in rheumatoid arthritis. Clin Rheumatol 2006;25:448-452
59. Aguillon JC, Cruzat A, Aravena O, Salazar L, Llanos C, Cuchacovich M. Could single-nucleotide polymorphisms (SNPs) affecting the tumour necrosis factor promoter be considered as part of rheumatoid arthritis evolution? Immunobiology 2006;211:75-84
60. Poli F, Boschiero L, Giannoni F, et al. Tumour necrosis factor-alpha gene polymorphism: implications in kidney transplantation. Cytokine 2000;12:1778-1783
61. Vinasco J, Beraun Y, Nieto A, et al. Polymorphism at the TNF loci in rheumatoid arthritis. Tissue Antigens 1997;49: 74-78
62. Huizinga TW, Keijsers V, Yanni G, et al. Are differences in interleukin 10 production associated with joint damage? Rheumatology (Oxford) 2000;39:1180-1188
63. Kirkham BW, Lassere MN, Edmonds JP, et al. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: A two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 2006;54:1122-1131
64. Ghosh K, Shankarkumar U, Shetty S, Mohanty D. Chronic synovitis and HLA B27 in patients with severe haemophilia. Lancet 2003;361:933-934
65. van Lent PL, Nabbe K, Blom AB, et al. Role of activatory Fc gamma RI and Fc gamma RIII and inhibitory Fc gamma RII in inflammation and cartilage destruction during experimental antigen-induced arthritis. Am J Pathol 2001;159:2309-2320
66. Roosendaal G, Lafeber FP. Pathogenesis of haemophilic arthropathy. Haemophilia 2006;12(Suppl 3):117-121
67. McDonald A, Hoffman M, Hedner U, Roberts HR, Monroe DM. Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B. J Thromb Haemost 2007;5:1577-1583
68. Conway EM, Collen D, Carmeliet P. Molecular mechanisms of blood vessel growth. Cardiovasc Res 2001;49:507-521
69. Ollivier V, Chabbat J, Herbert JM, Hakim J, de Prost D. Vascular endothelial growth factor production by fibroblasts in response to factor VIIa binding to tissue factor involves thrombin and factor Xa. Arterioscler Thromb Vasc Biol 2000;20:1374-1381
70. Jazwa A, Loboda A, Golda S, et al. Effect of heme and heme oxygenase-1 on vascular endothelial growth factor synthesis and angiogenic potency of human keratinocytes. Free Radic Biol Med 2006;40:1250-1263
71. Fearon U, Reece R, Smith J, Emery P, Veale DJ. Synovial cytokine and growth factor regulation of MMPs/TIMPs: implications for erosions and angiogenesis in early rheumatoid and psoriatic arthritis patients. Ann N Y Acad Sci 1999;878:619-621
72. Drouart M, Saas P, Billot M, et al. High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies. Clin Exp Immunol 2003;132:158-162
73. Butt C, Lim S, Greenwood C, Rahman P. VEGF, FGF1, FGF2 and EGF gene polymorphisms and psoriatic arthritis. BMC Musculoskelet Disord 2007;8:1
74. Oen K, Malleson PN, Cabral DA, et al. Cytokine genotypes correlate with pain and radiologically defined joint damage in patients with juvenile rheumatoid arthritis. Rheumatology (Oxford) 2005;44:1115-1121
75. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591-602
76. Mura C, Nousbaum JB, Verger P, et al. Phenotype-genotype correlation in haemochromatosis subjects. Hum Genet 1997;101:271-276
77. Alizadeh BZ, Njajou OT, Hazes JM, et al. The H63D variant in the HFE gene predisposes to arthralgia, Chondrocalcinosis and osteoarthritis. Ann Rheum Dis 2007; 66:1436-1442
78. Cruz E, Porto G, Morais S, Campos M, de Sousa M. HFE mutations in the pathobiology of hemophilic arthropathy. Blood 2005;105:3381-3382
79. Barnes C, Blanchette V, Lillicrap D, et al. Different clinical phenotype in triplets with haemophilia A. Haemophilia 2007;13:202-205
80. Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A 2005;102:10604-10609
81. Buzzard BM. Sports and hemophilia: antagonist or protagonist. Clin Orthop Relat Res 1996;328:25-30
82. Sahyoun NR, Hochberg MC, Helmick CG, Harris T, Pamuk ER. Body mass index, weight change, and incidence of self-reported physician-diagnosed arthritis among women. Am J Public Health 1999;89:391-394
83. Ahmed R, Kannan M, Choudhry VP, Saxena R. Does the MTHFR 677T allele alter the clinical phenotype in severe haemophilia A? Thromb Res 2003;109:71-72
84. Petkova R, Chakarov S, Horvath A, Ganev V, Kremensky I. Coexistence of a common prothrombotic risk factor and hemophilia in the Bulgarian hemophilic population:genotype/phenotype correlations. Balkan J Med Genet 2001;4: 37-39
85. Yee DL. Platelets as modifiers of clinical phenotype in hemophilia. Sci World J 2006;6:661-668
86. Skogen B, Bellissimo DB, Hessner MJ, et al. Rapid determination of platelet alloantigen genotypes by polymerase chain reaction using allele-specific primers. Transfusion 1994;34:955-960
87. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-3703
88. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67
89. Di Castelnuovo A, D'Orazio A, Amore C, et al. Genetic modulation of coagulation factor VII plasma levels: contribution of different polymorphisms and gender-related effects. Thromb Haemost 1998;80:592-597
90. Kangsadalampai S, Board P. The Val34Leu polymorphism in the A subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity. Blood 1998;92:2766-2770
91. Brouwers GJ, Leebeek FW, Tanck MW, Wouter Jukema J, Kluft C, de Maat MP. Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris. Thromb Haemost 2003;90:92-100
92. von Depka M, Czwalinna A, Eisert R, et al. Prevalence of a 23bp insertion in exon 3 of the endothelial cell protein C receptor gene in venous thrombophilia. Thromb Haemost 2001;86:1360-1362
93. Marsik C, Endler G, Halama T, et al. Polymorphism in the tissue factor region is associated with basal but not endotoxin-induced tissue factor-mRNA levels in leukocytes. J Thromb Haemost 2006;4:745-749
94. Heltianu C, Costache G, Azibi K, Poenaru L, Simionescu M. Endothelial nitric oxide synthase gene polymorphisms in Fabry's disease. Clin Genet 2002;61:423-429
95. Kim HS, Hwang KY, Chung IK, et al. Tissue plasminogen activator and plasminogen activator inhibitor type 1 gene polymorphism in patients with gastric ulcer complicated with bleeding. J Korean Med Sci 2003;18:58-64
96. Martiskainen M, Pohjasvaara T, Mikkelsson J, et al. Fibrinogen gene promoter -455 A allele as a risk factor for lacunar stroke. Stroke 2003;34:886-891
97. Amini-Nekoo A, Futers TS, Moia M, Mannucci PM, Grant PJ, Ariens R. Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis. Br J Haematol 2001;113:537-543
98. Spek CA, Koster T, Rosendaal FR, Bertina RM, Reitsma P. Genotypic variation in the promoter region of the protein C gene is associated with plasma protein C levels and thrombotic risk. Arterioscler Thromb Vasc Biol 1995;15: 214-218
99. Leroy-Matheron C, Duchemin J, Levent M, Gouault-Heilmann M. Genetic modulation of plasma protein S levels by two frequent dimorphisms in the PROS1 gene. Thromb Haemost 1999;82:1088-1092
100. Doggen CJ, Kunz G, Rosendaal FR, et al. A mutation in the thrombomodulin gene, 127G to A coding for Ala25Thr, and the risk of myocardial infarction in men. Thromb Haemost 1998;80:743-748
101. Tiret L, Rigat B, Visvikis S, et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 1992;51:197-205
102. Addas-Carvalho M, Origa AF, Saad ST. Interleukin 1 beta and tumor necrosis factor levels in stored platelet concentrates and the association with gene polymorphisms. Transfusion 2004;44:996-1003
103. Barber MD, Powell JJ, Lynch SF, Fearon KC. J.A. R. A polymorphism of the interleukin-1 beta gene influences survival in pancreatic cancer. Br J Cancer 2000;83:1443-1447
104. Tarlow JK, Blakemore AI, Lennard A, et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993;91:403-404
105. Messer G, Spengler U, Jung MC, et al. Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J Exp Med 1991;173:209-219
106. Rocha V, Franco RF, Porcher R, et al. Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002;100:3908-3918
107. Chae YS, Kim JG, Sohn SK, et al. Investigation of vascular endothelial growth factor gene polymorphisms and its association with clinicopathologic characteristics in gastric cancer. Oncology 2006;71:266-272